

UNCLASSIFIED

AD NUMBER
ADB249671
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Oct 98. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 23 Aug 2001

THIS PAGE IS UNCLASSIFIED

AD_____

GRANT NUMBER DAMD17-97-1-7198

TITLE: Breast Tumor Specific Peptides: Development of Breast
Carcinoma Diagnostic and Therapeutic Agents

PRINCIPAL INVESTIGATOR: Thomas Quinn, Ph.D.

CONTRACTING ORGANIZATION: University of Missouri-Columbia
Columbia, Missouri 65211

REPORT DATE: October 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Oct 98). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

DTIC QUALITY INSPECTED 4

19991208 168

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-97-1-7198

Organization: University of Missouri-Columbia

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Patricia M. Modrow

11/12/99

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1998		3. REPORT TYPE AND DATES COVERED Annual (1 Oct 97 - 30 Sep 98)	
4. TITLE AND SUBTITLE Breast Tumor Specific Peptides: Development of Breast Carcinoma Diagnostic and Therapeutic Agents				5. FUNDING NUMBERS DAMD17-97-1-7198	
6. AUTHOR(S) Quinn, Thomas, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Missouri-Columbia Columbia, Missouri 65211				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Oct 98). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The goal of the proposed research is to develop breast tumor-avid peptides as potential in vivo imaging or therapeutic agents. Peptides that specifically bound two breast tumor antigens, the Thomsen-Friedenreich (T) antigen and the erb-B2 receptor, were identified from random peptide bacteriophage display libraries. The T antigen-avid peptides were labeled with ^{99m} Tc and shown to be radiochemically stable and bind cultured human breast tumor cells in vitro. In vivo biodistribution studies performed in normal mice showed that the peptides were stable in vivo and exhibited whole body clearance primarily through the GI tract. Tumor targeting studies with the ^{99m} Tc-labeled peptides will begin shortly in breast tumor bearing mice. In addition, bacteriophage display libraries, displaying random peptides of various lengths, were screened with recombinant erbB-2 extracellular domain protein. Sequencing of erbB-2 binding clones has yielded the first consensus peptide. More clones, will be sequenced and analyzed to identify additional erbB-2 binders. The erbB-2 binding peptides will be chemically synthesized, radiolabeled, and examined for their abilities to bind breast tumor cells in vitro and in vivo.					
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 12	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited		

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

10/29/78
Date

TABLE OF CONTENTS:

INTRODUCTION	5
BACKGROUND OF PREVIOUS WORK	5
METHODS AND RESULTS	5
T ANTIGEN BINDING PEPTIDES	5
erbB-2 RECEPTOR BINDING PEPTIDES	8
DISCUSSION WITH RELATIONSHIP TO STATEMENT OF WORK	10
CONCLUSIONS	10
REFERENCES	11

INTRODUCTION:

The focus of our DoD funded research program is to identify peptides that specifically bind two breast tumor antigens, the Thomsen-Friedenreich (T) antigen and the erb-B2 receptor, radiolabel the peptides with ^{99m}Tc and ^{188}Re , and determine the abilities of the radiolabeled peptides to target breast tumors in a scid mouse model system. The goal of this work is to develop breast tumor-avid peptides as potential *in vivo* imaging or therapeutic agents.

Background of previous work: T antigen is a disaccharide ($\text{Gal}\beta 1 \rightarrow 3\text{GalNAc}$) which is masked on the surface of healthy cells, but is exposed and immuno-reactive on the surfaces of most tumor cells (1), particularly breast carcinoma cells (2). Peptides that bound T antigen were identified from a random peptide phage display library, screened with two glycoproteins which display T antigen on their surfaces, asialofetuin and a BSA-T conjugate. Eight-hundred affinity selected clones were sequenced. The most frequently occurring phage clones, P10, had the sequence; Gly-Ser-Trp-Tyr-Ala-Trp-Ser-Pro-Leu-Val-Pro-Ser-Ala-Gln-Ile. P10 and next most frequent sequence P30 (His-Gly-Arg-Phe-Ile-Leu-Pro-Trp-Trp-Tyr-Ala-Phe-Ser-Pro-Ser) were chemically synthesized. Fluorescence quenching titration assays were used to measure the dissociation constants (K_d s) for P10 and P30 binding to T antigen present on asialofetuin. P10 and P30 exhibited K_d s of 100 nM and 0.1 μM , respectively, for binding the T antigen structure *in vitro*. The ability of P10 and P30 to interact with the native conformation of T antigen presented on tumor cells was confirmed by visualization of biotinylated-P10 and -P30 bound to MDA-MB435 human breast carcinoma cells. Biotin was attached to the amino termini of the peptides. Biotinylated-P10 and -P30 were detected by the binding of a streptavidin-horseradish peroxidase conjugate and subsequent catalysis of the chromogenic substrate DAB. Biotinylated-P10 and -P30 bound to the MDA-MB435 human breast carcinoma cells, and were competed off by the presence of excess non-biotinylated peptide. The presence of T antigen on the MDA-MB435 cells was confirmed by binding of a peroxidase-peanut lectin conjugate. Murine melanoma B16-F1 cells, which do not display T antigen, were used as a negative control. These results were published in the *Journal of Molecular Biology* (3). Our goal was to radiolabel P10 and P30 and examine their potential as breast tumor imaging agents.

BODY:

Results:

A. T- Antigen Project:

1. Radiolabeling T antigen peptides:

Analogues of the T antigen binding peptides P10 and P30 were synthesized with either an acetylated-Cys-Gly-Cys-Gly (Ac-CGCG) or Cys-Gly-Cys-Gly (CGCG) tetrapeptide appended to their amino termini (Table 1)

Table 1. Peptide Synthesized

Name	Peptide Sequence
Ac-CGCG-P30	Ac-CGCG-HGRFILPW WYAF SPS
Ac-CGCG-P54	Ac-CGCG-WHR WYAW SP
CGCG-P54	CGCG-WHR WYAW SP
Ac-CGCG-P55	Ac-CGCG-R WYAW SP
CGCG-P55	CGCG-R WYAW SP
Ac-CGCG-P10	Ac-CGCG-G SWYAW SPLVPSA QI

* Putative T antigen binding sequences are highlighted in bold type.

We had previously shown that the CGCG peptide was able to coordinate $^{186/188}\text{Re}$ and ^{99m}Tc when it was attached to the N-terminus of polypeptide (4). The peptides in Table 1 were synthesized on an ABI-432 amino acid synthesizer using standard Fmoc solid phase peptide synthesis (SPPS) chemistry (4). Peptides were cleaved from the resin with a 95:5 trifluoroacetic acid (TFA):water

mixture and deprotected in a 50:10:40 TFA:thioanisole:water mixture, ether precipitated, and lyophilized. Peptide preparations were purified to homogeneity on a Vydac C-18 reverse-phase (RP) column using high performance liquid chromatography (HPLC). The masses of the purified peptides were determined by fast-atom bombardment mass spectroscopy (FAB-MS). The predicted masses of Ac-CGCG-P10 and -P30 agreed with the experimentally determined values.

The T antigen binding properties of Ac-CGCG-P10 and -P30 were examined in vitro by fluorescence quenching experiments as previously described in the background section. It was important to demonstrate that the addition of the N-terminal radiometal coordination tetrapeptide did not effect T antigen binding. The K_d values for the Ac-CGCG-P10 and -P30 peptides were the same as the values determined for P10 and P30, within experimental error, indicating that the additional amino acids did not effect T antigen binding. Ac-CGCG- and CGCG- containing peptides were radiolabeled with ^{99m}Tc directly via a glucoheptonate transchelation reaction (4, 5). Briefly, $^{99m}\text{TcO VII}$ was reduced to $^{99m}\text{TcO V}$ by stannous chloride in the presence of glucoheptoic acid, forming a $^{99m}\text{TcO V}$ -glucoheptonate complex. Peptide was added to the reaction mixture and the pH of the solution was adjusted to 7.0 with NaOH. The reaction mixture was refluxed at 80°C for 40 min. Under these conditions, the Cys sulfurs of the CGCG sequence form a more favorable $^{99m}\text{TcO V}$ coordination complex than glucoheptonate, which drives the peptide radiolabeling reaction. The stabilities of ^{99m}Tc labeled peptides were examined after a 24 hr incubation in phosphate buffered saline, pH 7.4 (PBS) and in PBS containing 4 mM cysteine (Table 2).

Table 2 Stability of Radiolabeled Peptides in PBS and PBS+ Cysteine 24 hr post purification.

Tc-99m-Radiolabeled Peptides	In PBS(10mM)	Cysteine(4mM)
Tc-99m-Ac-CGCG-P30	N.D.	N.D.
Tc-99m-Ac-CGCG-P10	N.D.	N.D.
Tc-99m-Ac-CGCG-P54	N.D.	40% remain
Tc-99m-CGCG-P54	N.D.	90% remain
Tc-99m-Ac-CGCG-P55	N.D.	30% remain
Tc-99m-CGCG-P55	N.D.	40% remain

*N. D.= No degradation

The radiolabeled peptide were injected on a C-18 RP column which is capable of separating labeled peptide from pertechnetate (free ^{99m}Tc). The results indicated that the ^{99m}Tc labeled peptides were stable in vitro over a 24 hr time period. In addition, the radiolabeled peptide were resistant to chemical challenges from free cysteine

2. Cell Binding Experiments:

Cell binding experiments were performed with cultured human breast cancer MDA-MB-435 cells (Table 3). T antigen expression on MDA-MB-435 cells was confirmed by a positive binding reaction with peanut lectin (3).

Table 3. Cell binding to MB435 for technetium labeled peptides 4°C for 1.5hr

Peptide	TB ¹	NSB ²	SB ³
Ac-CGCG-P30	27.7%	11.0%	16.7%
Ac-CGCG-P54	4.65%	2.23%	2.42%
Ac-CGCG-P55	1.12%	0.75%	0.37%
Ac-CGCG-P10	5.12%	4.54%	0.58%

¹TB, total binding; ²NSB, non-specific binding; ³SB, specific binding.

Briefly, 2×10^6 cells were mixed with approximately 100,000 cpm of a radiolabeled peptide. The mixture was allowed to incubate at 4°C for 2 hrs. The cells were washed 2x with PBS and counted to determine total binding. Non-specific binding experiments were performed in a similar fashion

except that a 1000-fold excess of unlabeled peptide was present. Specific binding was determined by subtracting the non-specific binding from total binding. The P30 and P54 peptides exhibited the highest specific binding values. In all cases, the non-specific binding was fairly high. This could be due to peptide precipitation caused by the addition of the excess cold peptide. We are repeating our binding assays in different buffers and in larger volumes to determine if peptide precipitation contributes significantly to the non-specific binding numbers.

3. Animal Experiments:

The biodistribution of ^{99m}Tc labeled Ac-CGCG-P30, -P54, -P55, -P10, and CGCG-P54 and -P55 were examined in C57BL/6 normal mice. Mice were injected with 3-5 μCi of a radiolabeled peptide. At various times post injection, the mice were sacrificed and specific tissues were counted. Results from the biodistribution experiments are presented in Tables 4 and 5 as percent dose per gram or as percent of injected dose, respectively.

Table 4. Biodistribution of ^{99m}Tc -peptides in C57BL/6 normal mice 1hr post-injection reported as % injected dose/gram, (n=4 $\pm$ SD).

Tissue	Ac-CGCG-P30	CGCG-P54	Ac-CGCG-P54	CGCG-P55	Ac-CGCG-P55	Ac-CGCG-P10
Brain	0.09 $\pm$ 0.02	0.02 $\pm$ 0.02	0.02 $\pm$ 0.02	0.01 $\pm$ 0.02	0.02 $\pm$ 0.01	
Blood	2.24 $\pm$ 0.43	0.38 $\pm$ 0.07	0.59 $\pm$ 0.05	0.13 $\pm$ 0.07	0.90 $\pm$ 0.04	7.24 $\pm$ 2.73
Heart	0.55 $\pm$ 0.07	0.09 $\pm$ 0.06	0.24 $\pm$ 0.08	0.12 $\pm$ 0.12	0.26 $\pm$ 0.06	1.38 $\pm$ 0.72
Lung	1.35 $\pm$ 0.26	0.22 $\pm$ 0.04	1.10 $\pm$ 0.20	0.15 $\pm$ 0.02	0.57 $\pm$ 0.20	2.16 $\pm$ 1.26
Liver	47.04 $\pm$ 5.28	2.96 $\pm$ 1.56	2.07 $\pm$ 0.55	4.59 $\pm$ 1.75	1.43 $\pm$ 0.40	13.86 $\pm$ 1.26
Spleen	1.05 $\pm$ 0.14	0.06 $\pm$ 0.03	0.24 $\pm$ 0.10	0.07 $\pm$ 0.06	0.30 $\pm$ 0.18	0.92 $\pm$ 0.13
Stomach	3.77 $\pm$ 3.18	0.88 $\pm$ 0.57	2.20 $\pm$ 0.86	0.55 $\pm$ 0.32	6.38 $\pm$ 1.31	2.04 $\pm$ 0.75
Intestines	13.60 $\pm$ 3.05	33.53 $\pm$ 4.40	35.27 $\pm$ 2.94	28.24 $\pm$ 1.39	33.74 $\pm$ 3.97	31.49 $\pm$ 1.45
Larger I.	1.12 $\pm$ 1.30	3.53 $\pm$ 5.94	23.29 $\pm$ 37.36	5.19 $\pm$ 6.19	33.88 $\pm$ 22.91	0.99 $\pm$ 0.69
Small I.	21.60 $\pm$ 4.19	48.08 $\pm$ 8.52	41.76 $\pm$ 18.38	40.26 $\pm$ 2.00	33.60 $\pm$ 15.84	48.26 $\pm$ 2.33
Kidneys	2.42 $\pm$ 0.23	0.83 $\pm$ 0.12	2.41 $\pm$ 1.18	1.75 $\pm$ 0.23	1.18 $\pm$ 0.04	2.53 $\pm$ 0.14
Muscle	0.11 $\pm$ 0.10	0.16 $\pm$ 0.04	0.15 $\pm$ 0.06	0.09 $\pm$ 0.08	0.14 $\pm$ 0.05	0.28 $\pm$ 0.07
Pancreas	0.50 $\pm$ 0.12	0.63 $\pm$ 0.50	0.29 $\pm$ 0.09	0.08 $\pm$ 0.05	0.32 $\pm$ 0.04	0.74 $\pm$ 0.24

*I.; Intestines

Results from the initial biodistribution experiments indicated that the primary route of clearance for these T antigen binding peptides was through the gastrointestinal (GI) tract. All of the peptides show low uptake in the organs around the breast (i.e. lungs and heart), except for P10 which display slightly elevated activity levels in the lungs. There was good clearance from the blood and low liver uptake for P54 and P55, while the longer peptides showed higher liver values. It was no surprise that the primary route of peptide clearance was through the GI tract given the hydrophobic nature of the P10 and P30 sequences. Removing some of the non-essential hydrophobic residues of P10 and P30 resulted in the P54 and P55 sequences. It was hypothesized that increasing the hydrophilic nature of the peptides would improve their clearance. The biodistribution patterns of the P54 and P55 peptides indicated that their was less liver uptake and better blood clearance, but the primary route of clearance was still through the GI tract. These results suggested that the hydrophobic nature of the ^{99m}Tc [Ac-CGCG] complex may have a dominant impact on the peptide's clearance properties. Experiments are currently underway to investigate the role of the ^{99m}Tc [Ac-CGCG] complex in the biodistribution of our T antigen binding peptides. The presence or absence of the acetyl group on the N-terminal cysteine did not appear to have an effect on the stability of the peptides in vivo. Many peptides are rapidly proteolyzed in vivo. N-terminal acetylation affords peptides some degree of resistance to proteolysis. The fact that the N-terminal residues of the

radiolabeled T antigen peptides are involved in metal coordination may prevent them from being recognized by proteases in vivo.

Table 5. Biodistribution of ^{99m}Tc -peptides in C57BL/6 normal mice 1hr post-injection reported as % injected dose, (n=4 $\pm$ SD).

Tissue	Ac-CGCG-P30	CGCG-P54	Ac-CGCG-P54	CGCG-P55	Ac-CGCG-P55	Ac-CGCG-P10
Brain	0.04 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.01 $\pm$ 0.00	0.00 $\pm$ 0.00	
Blood	3.47 $\pm$ 0.77	0.82 $\pm$ 0.07	0.55 $\pm$ 0.12	1.28 $\pm$ 0.07	0.18 $\pm$ 0.09	0.79 $\pm$ 0.43
Heart	0.05 $\pm$ 0.00	0.02 $\pm$ 0.00	0.00 $\pm$ 0.00	0.02 $\pm$ 0.00	0.01 $\pm$ 0.01	0.16 $\pm$ 0.00
Lung	0.25 $\pm$ 0.11	0.16 $\pm$ 0.03	0.03 $\pm$ 0.00	0.10 $\pm$ 0.01	0.02 $\pm$ 0.00	0.38 $\pm$ 0.10
Liver	49.23 $\pm$ 1.28	2.64 $\pm$ 0.57	3.69 $\pm$ 2.08	1.99 $\pm$ 0.73	5.54 $\pm$ 2.16	16.59 $\pm$ 1.97
Spleen	0.07 $\pm$ 0.01	0.02 $\pm$ 0.01	0.00 $\pm$ 0.00	0.02 $\pm$ 0.01	0.01 $\pm$ 0.01	0.07 $\pm$ 0.01
Stomach	0.62 $\pm$ 0.45	1.05 $\pm$ 0.29	0.33 $\pm$ 0.15	3.78 $\pm$ 0.09	0.21 $\pm$ 0.11	0.38 $\pm$ 0.14
Intestines	25.84 $\pm$ 1.04	70.00 $\pm$ 1.74	75.78 $\pm$ 3.36	73.19 $\pm$ 1.87	65.66 $\pm$ 1.88	58.40 $\pm$ 3.28
Large Int.	0.94 $\pm$ 1.21	14.77 $\pm$ 23.5	2.52 $\pm$ 4.21	25.00 $\pm$ 17.4	3.93 $\pm$ 4.66	0.58 $\pm$ 0.39
Small Int.	24.89 $\pm$ 0.84	55.22 $\pm$ 23.1	73.26 $\pm$ 4.51	48.18 $\pm$ 18.5	61.72 $\pm$ 4.44	51.83 $\pm$ 3.44
Kidneys	0.69 $\pm$ 0.01	0.65 $\pm$ 0.04	0.25 $\pm$ 0.04	0.36 $\pm$ 0.03	0.54 $\pm$ 0.04	0.76 $\pm$ 0.06
Muscle	0.01 $\pm$ 0.01	0.01 $\pm$ 0.00	0.01 $\pm$ 0.00	0.01 $\pm$ 0.00	0.00 $\pm$ 0.00	0.03 $\pm$ 0.00
Pancreas	0.13 $\pm$ 0.02	0.05 $\pm$ 0.01	0.14 $\pm$ 0.10	0.06 $\pm$ 0.01	0.01 $\pm$ 0.01	0.17 $\pm$ 0.02
Urine	15.02 $\pm$ 0.54	20.99 $\pm$ 2.55	17.28 $\pm$ 1.16	1.26 $\pm$ 0.69	26.55 $\pm$ 1.15	9.68 $\pm$ 0.43
Carcass	7.43 $\pm$ 0.16	4.23 $\pm$ 0.69	2.32 $\pm$ 0.51	5.42 $\pm$ 0.30	2.32 $\pm$ 0.51	18.58 $\pm$ 3.00

*I.;Intestines

B. erbB-2 Project:

1. Expression and Purification of erbB-2:

The erbB-2 extra cellular domain (ecd) gene, containing a C-terminal FLAGTM tag, engineered into the eukaryotic expression vector pRC/CMV (Invitrogen) was obtained from Dr. Fiddes at the CRC for Biopharmaceutical Research PTY LTD, Australia. This expression system was reported to secrete 0.5-1 μg of erbB-2ecd/ml of culture media (6). The erbB-2ecd expression plasmid, was transfected into immortalized human embryonic kidney (HEK-293) cells. The transfected cultures were placed under geneticin selection since the erbB-2 plasmid also contained a Neo resistance gene. Individual cell clones were isolated and expanded into clonal cell lines. Culture media samples from individual erbB-2 containing KB cells lines were examined for the presence of the recombinant erbB-2 protein. Cell culture media samples were concentrated 10x and used to coat enzyme-linked immunosorbant assay (ELISA) plate wells at various dilutions for 2 hr at 25°C. The wells were blocked with a bovine serum albumin (BSA)/Tween-20 solution prior to the addition of a mouse anti-erbB-2 extracellular domain antibody. An anti-mouse Fc antibody conjugated to alkaline phosphatase was employed for detection purposes. The ELISA assay was developed with the chromogenic substrate p-Nitrophenyl phosphate. This ELISA assay allowed us to determine which clone was secreting the most erbB-2 protein. The identity of the secreted protein was confirmed by Western blot analysis (Figure 1A). Aliquots from the concentrated media samples were run on reducing 10 % sodium dodecyl sulfate (SDS)-polyacrylamide gels and transferred to nitrocellulose. The Western blots were developed by the same antibody combination used in the ELISAs described above. A strong signal with an apparent molecular weight of ~90 KD was visualized. Clone # 7 was chosen for further amplification and protein production. The erbB-2 ecd protein was purified by affinity chromatography using anti-FLAG tag resin (Sigma Chemical). Briefly, 100-200 ml of culture supernatant was passed over a 5ml FLAG affinity column. The column was washed with 200 ml of TBS [20 mM Tris-HCl (pH 8.0), 150 mM NaCl]. The erbB-2ecd protein was eluted with 0.1 M glycine-HCl, pH 3.0. The pH of the erbB-

2ecd containing samples were immediately adjusted to ~8 by addition of 0.1 volume 1 M Tris-HCl, pH 8.0. The protein yields from this purification averaged 0.8 $\mu\text{g}/\text{ml}$ of culture media. Samples of the protein were analyzed by reducing SDS-polyacrylamide gel electrophoresis (PAGE). As depicted in Figure 1B., a homogeneous protein species with a molecular weight of ~95 KD was present. Approximately 80 μg s of erbB-2ecd was purified for use in phage library maturation experiments.

Figure 1.




Figure 1. Analysis of erbB-2-ecd. (1A) Western blot analysis of cell culture media from cells clones expressing the erbB-2-ecd protein. (1B) SDS-PAGE analysis of erbB-2ecd after affinity purification. Lanes 1 and 2 are different concentrations of the purified erbB-2ecd preparation. Molecular weight markers (MW) are reported in kiloDaltons (kD).

2. Affinity maturation of peptide phage display libraries with erbB-2:

Two phage display libraries, exhibiting either 15 or 6 amino acid random peptides, were screened with the purified erbB-2ecd protein. The erbB-2ecd protein was biotinylated at a ratio of 2 biotin molecules per protein molecule in a aqueous reaction with N-hydroxysuccinimide (NHS)-biotin. Free biotin was removed from the protein preparation by G-25 size-exclusion chromatography. The affinity maturation procedure took place in 22 mm tissue culture plates. The biotinylated erbB-2ecd protein was incubated in streptavidin or neutravidin coated plates overnight at 4° C. The plates were washed with TBS and blocked with a solution of 1% BSA in TTBS [20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Tween-20] for 2 hrs at 25°C. One plate was incubated with an anti-erbB-2ecd antibody to confirm the present of erbB-2ecd on the plates prior to performing the affinity maturation experiments. Initially, a solution containing 13 μg of erbB-2ecd was used to coat the plates. 1 x 10¹¹ phage particles from either the 15 or 6 mer library were added to the erbB-2ecd coated plates in TTBS. The plates were incubated at 25°C for 2 hrs, then washed extensively with TTBS to remove unbound phage particles. Bound phage particles were eluted from the plates in 0.1 M glycine-HCl, pH 2.2. The eluted phage were used to infect a fresh culture of *E. coli* to amplify the selected population used in the next round a affinity maturation. Round two began with the input phage obtained from round 1 after amplification. The same selection protocol was used as

in round 1 except less biotinylated erbB-2ecd was attached to the plate. Each subsequent round of affinity maturation had less erbB-2ecd on the plate to increase the stringency of selection. In addition, neutravidin was used in round 3 and 4 instead of streptavidin to reduce non-specific binding. Table 6 lists the amount of erbB-2ecd used in each round and the input and output phage values obtained in the affinity maturation procedure.

Table 6: Affinity maturation efficiencies per round of selection.

	Round 1	Round 2	Round 3	Round 4
[biotin- erbB-2ecd] Plate coating	13 µg streptavidin	5.2 µg streptavidin	1 µg neutravidin	0.1 µg neutravidin
Inputs	6mer 1.3x10 ¹¹ 15mer 1.3x10 ¹¹	6mer 1.0x10 ¹¹ 15mer 8.0x10 ¹⁰	6mer 1.2x10 ¹⁰ 15mer 2.8x10 ¹⁰	6mer 6.6x10 ⁹ 15mer 6.0x10 ⁹
Outputs	6mer 2.0x10 ⁴ 15mer 2.2x10 ⁴	6mer 2.2x10 ⁵ 15mer 2.6x10 ⁵	6mer 9.2x10 ⁴ 15mer 1.4x10 ⁵	6mer 2.7x10 ⁶ 15mer 2.4x10 ⁶
Percent yields	6mer 1.5x10 ⁻⁵ 15mer 1.2x10 ⁻⁵	6mer 2.2x10 ⁻⁴ 15mer 3.3x10 ⁻⁵	6mer 3.1x10 ⁻³ 15mer 2.0x10 ⁻³	6mer 4.1x10 ⁻² 15mer 3.9x10 ⁻²

3. Sequence of erbB-2 binding peptides:

Phage colons obtained from round 4 of the affinity selection procedure were isolated and prepared for sequencing. First, clones from the 15mer library were sequenced. Thus far, the region of the CPIII gene encoding the random peptide inserts from 85 clones have been sequenced. 95% of these clones had the same peptide amino acid sequence. The sequence is; Trp-Arg-Arg-Trp-Phe-Tyr-Gln-Phe-Pro-Thr-Pro-Leu-Ala-Ala-Ala. Additional clones from the 15mer library as well as 100s of clones from the 6mer library will be sequenced to identify polypeptide sequences that bind erbB-2.

Discussion in relationship to Statement of Work:

The two tasks outlined for the first 12 months in the statement of work for this proposal were to synthesize and radiolabel T antigen peptides and identify peptide sequences that bound purified erbB-2.

Task 1: We have synthesized and radiolabeled the T antigen binding peptides P30 and P10 plus several analogs based on their conserved chemical structures. Radiochemical stabilities as well as in vitro cell binding assays have been performed with the ^{99m}Tc labeled peptides.

Task 2: (12-24 months). In vivo biodistribution and tumor targeting experiments will be performed in normal and breast tumor bearing scid mice. We have already begun in vivo biodistribution studies in normal mice to examine peptide stability and clearance patterns.

Task 3: Immortalized human cell lines expressing the extracellular domain of erbB-2 have been established. These cell lines secrete protein which is reactive with anti-erbB-2 antibodies. An affinity purification protocol has been worked out for isolating erbB-2 from the cell culture media. Purification yields for this process are 0.8 µg/ml of tissue culture media. The purified protein was used to identify peptide sequences that bound erbB-2 from random peptide phage display libraries. Initial clones from these affinity maturation procedures have been sequenced.

The remaining tasks are all scheduled for years 2 and 3.

CONCLUSIONS:

During the first 12 months of this project all of the important foundation tasks have been accomplished. We have been successful at radiolabeling our T antigen binding peptides and have shown that they are radiochemically stable. We have also been able to establish the expression of

the erbB-2-ecd protein in cultured human embryonic kidney cell lines. Affinity purification procedures have produced purified erbB-2-ecd used in screening the random peptide phage display libraries. The most important results so far are that we have begun to evaluate the ^{99m}Tc labeled T antigen peptides in vivo. The radiolabeled peptide appear to be radiochemically stable and resistant to proteolysis in vivo. Equally exciting results are being obtained from screening the random peptide phage display libraries with the erbB-2-ecd protein. A putative 15 amino acid peptide that binds erbB-2 has been identified from one of the phage libraries. This peptide will be chemically synthesized and examined for its ability to bind the erbB-2 receptor on human breast carcinoma cells.

REFERENCES:

1. Springer, G. F. *Science* **224**, 1198-1206 (1985).
2. Springer, G. F. *Molecular Immunology* **26**, 1-5 (1989).
3. Peletskaya, E. N., Glinsky, V., Glinsky, G. V., Deutscher, S. L., Quinn, T. P. *Journal of Molecular Biology*, **270**, 374-384 (1997).
4. Giblin, M. F., Jurisson, S. S., Quinn, T. P. *Bioconj. Chem.* **8**, 347-353 (1997).
5. Giblin, M. F., Wang, N., Hoffman, T.J., Jurisson, S. S., Quinn, T.P. *Proc. Natl. Acad. Sci. USA* (In press).
6. Clark, M. A., Hawkins, N. J., Papaioannou, A., Fiddes, R. J., Ward, R. L. *Clin. Exp. Immunol.* **109**, 166-174 (1997).



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

23 Aug 01

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to the technical reports listed at enclosure. Request the limited distribution statement for these reports be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management

Reports to be Downgraded to Unlimited Distribution

ADB241560	ADB253628	ADB249654	ADB263448
ADB251657	ADB257757	ADB264967	ADB245021
ADB263525	ADB264736	ADB247697	ADB264544
ADB222448	ADB255427	ADB263453	ADB254454
ADB234468	ADB264757	ADB243646	
ADB249596	ADB232924	ADB263428	
ADB263270	ADB232927	ADB240500	
ADB231841	ADB245382	ADB253090	
ADB239007	ADB258158	ADB265236	
ADB263737	ADB264506	ADB264610	
ADB239263	ADB243027	ADB251613	
ADB251995	ADB233334	ADB237451	
ADB233106	ADB242926	ADB249671	
ADB262619	ADB262637	ADB262475	
ADB233111	ADB251649	ADB264579	
ADB240497	ADB264549	ADB244768	
ADB257618	ADB248354	ADB258553	
ADB240496	ADB258768	ADB244278	
ADB233747	ADB247842	ADB257305	
ADB240160	ADB264611	ADB245442	
ADB258646	ADB244931	ADB256780	
ADB264626	ADB263444	ADB264797	